
The artificial sweetener erythritol and cardiovascular event risk

In the format provided by the
authors and unedited

Table of Contents

Supplementary Figures

Figure S1: Example of the gating strategy used for platelet flow cytometry experiments	2
--	---

Supplementary Tables

Table S1: Clinical characteristics of the discovery cohort	3
Table S2: Clinical characteristics of the US validation cohort	4
Table S3: Clinical characteristics of the European validation cohort	5
Table S4: Hazard ratios for 3-year MACE for the covariates used in the adjusted Cox models in the discovery cohort	6
Table S5: Hazard ratios for 3-year MACE for the covariates used in the adjusted Cox models in the US validation cohort	7
Table S6: Hazard ratios for 3-year MACE for the covariates used in the adjusted Cox models in the European validation cohort	8
Table S7: Gender-stratified Cox models for 3-year MACE for erythritol quartiles in the discovery cohort	9
Table S8: Gender-stratified Cox models for 3-year MACE for erythritol quartiles in the US validation cohort	10
Table S9: Gender-stratified Cox models for 3-year MACE for erythritol quartiles in the European validation cohort	11
Table S10: Hazard ratios for 3-year MACE for erythritol quartiles (Q4 vs. Q1) in different subgroups of the US validation cohort	12
Table S11: Hazard ratios for 3-year MACE for erythritol quartiles (Q4 vs. Q1) in different subgroups of the European validation cohort	13
Table S12. Cox regression models in the discovery cohort	14
Table S13. Cox regression analysis in US validation cohort	15
Table S14. Cox regression analysis in the European validation cohort	16

Supplementary figures:




Figure S1: Example of the gating strategy used for platelet flow cytometry experiments. Human washed platelets were exposed to vehicle (saline), stimulated with 2 μ M ADP and incubated with anti-P-selectin antibody (CD62P-PE). The sample was analyzed on a FACS LSR Fortessa flow cytometer. Platelets were gated to exclude doublets and the raw mean fluorescent intensity (MFI) was quantified. Twenty thousand events were collected.

Supplementary tables:

Table S1: Clinic characteristics of the discovery cohort

Characteristics	Quartile 1 (n=290)	Quartile 2 (n=289)	Quartile 3 (n=289)	Quartile 4 (n=289)	p
Age (yr)	59.8(51.9-69)	61.3(54.1-70.5)	66.5(57.4-72.5)	70.2(61.8-76)	<0.001
Male (%)	69.3	68.5	62.3	54.3	<0.001
BMI (kg/m ²)	27.8(24.9-31.6)	28.4(25.2-31.2)	28.7(25.6-31.9)	28.7(25.9-33.6)	0.04
Diabetes mellitus (%)	14.8	13.1	23.5	36.7	<0.001
Hypertension (%)	59.7	61.9	67.1	65.4	0.24
Current smoking (%)	15.9	17.3	12.1	9.4	0.02
CAD (%)	75.9	78.2	70.6	77.5	0.14
Heart failure (%)	22.1	21.0	24.3	33.3	0.02
History of MI (%)	45.5	44.7	45.1	50.0	0.57
LDL-c (mg/dl)	100(82-118)	96(80-117)	97(83-112)	93(76-114)	0.05
HDL-c (mg/dl)	34(29-42)	34(28-40)	34(28-41)	33.9(27-40)	0.22
Total cholesterol (mg/dl)	163(145-187)	160(141-188)	164(143-185)	161(139-188)	0.86
Triglycerides (mg/dl)	110(75-153)	119(82-170)	123(85-161)	136(96-201)	<0.001

The baseline characteristics of participants in the discovery cohort are shown stratified by erythritol quartiles. Continuous data are presented as median (interquartile range). Categorical variables are presented as %. BMI, body mass index; CAD, coronary artery disease; HDL, high density lipoprotein; LDL, low density lipoprotein; MI, myocardial infarction. Two-sided P values were calculated by Kruskal-Wallis test for numerical data and Chi-Square test for categorical data comparing erythritol quartiles. n=1,157.

Table S2: Clinical characteristics of the US validation cohort

Characteristics	Quartile 1 (n=542)	Quartile 2 (n=534)	Quartile 3 (n=540)	Quartile 4 (n=533)	p
Age (yr)	57.5(51-64)	60.5(54-67)	64.8(57-72)	70(60-76)	<0.001
Male (%)	66.6	65.9	65.0	58.5	0.02
BMI (kg/m ²)	28.5(25.1-31.9)	28.3(25.6-31.6)	28.7(25.9-32.5)	28.1(25.3-32.9)	0.30
Diabetes mellitus (%)	12.4	15.7	23.9	36.6	<0.001
Hypertension (%)	61.4	62.7	64.3	64	0.76
Current smoking (%)	16.4	14.5	8.6	11.4	0.001
CAD (%)	66.7	71.1	77.4	85.0	<0.001
Heart failure (%)	16.1	21.2	26.7	37.9	<0.001
History of MI (%)	30.9	35.9	41.2	50.1	<0.001
LDL-c (mg/dl)	99(80-120)	99.5(79-120)	94(76-116)	93(73-111)	<0.001
HDL-c (mg/dl)	35(29-43)	35(29-42)	34(28-41)	32(26-38)	<0.001
Total cholesterol (mg/dl)	162(140-187)	163(143-191)	160(137-186)	158(132-184)	0.005
Triglycerides (mg/dl)	103(77-139)	111(82-161)	119(87-159)	131(93-188)	<0.001

The baseline characteristics of participants in the US validation cohort are shown stratified by erythritol quartiles. Continuous data are presented as median (interquartile range). Categorical variables are presented as %. BMI, body mass index; CAD, coronary artery disease; HDL, high density lipoprotein; LDL, low density lipoprotein; MI, myocardial infarction. Two-sided P values were calculated by Kruskal-Wallis test for numerical data and Chi-Square test for categorical data comparing erythritol quartiles. n=2,149.

Table S3: Clinical characteristics of the European validation cohort

Characteristics	Quartile 1 (n=209)	Quartile 2 (n=211)	Quartile 3 (n=205)	Quartile 4 (n=208)	p
Age-yr	67(59-76)	72(65-79)	77(69-82)	79(73-85)	<0.001
Male (%)	71.8	73.5	64.9	70.2	0.25
Diabetes mellitus (%)	13.4	19.4	32.2	46.6	<0.001
Hypertension (%)	75.6	79.6	82.4	84.1	0.14
Current smoking (%)	29.7	14.7	10.2	12.5	<0.001
CAD (%)	64.6	65.4	68.3	78.8	0.005
Heart failure (%)	54.3	60.7	68.8	83.6	<0.001
History of MI (%)	44.0	46.4	46.6	61.5	0.001
LDL-c (mg/dl)	98(71-131)	96(71-130)	91(72-121)	82(64-105)	<0.001
HDL-c (mg/dl)	49(40-62)	49(39-60)	48(40-62)	45(36-57)	0.06
Total cholesterol (mg/dl)	162(137-197)	165(136-199)	167(136-198)	156(129-180)	0.05
Triglycerides (mg/dl)	121(89-172)	111(87-163)	115(90-160)	133(95-174)	0.19

The baseline characteristics of participants in the European validation cohort are shown stratified by erythritol quartiles. Continuous data are presented as median (interquartile range). Categorical variables are presented as %. BMI, body mass index; CAD, coronary artery disease; HDL, high density lipoprotein; LDL, low density lipoprotein; MI, myocardial infarction. Two-sided P values were calculated by Kruskal-Wallis test for numerical data and Chi-Square test for categorical data comparing erythritol quartiles. n=833.

Table S4: Hazard ratios for 3-year MACE for the covariates used in the adjusted Cox models in the discovery cohort

	HR with 95% CI	P value
Age	1.06 (0.85 - 1.34)	0.59
Gender	1.10 (0.70 - 1.72)	0.69
Blood pressure	1.05 (0.88 - 1.26)	0.59
Diabetes	1.23 (0.79 - 1.91)	0.36
Smoking	1.28 (0.73 - 2.25)	0.39
LDL cholesterol	1.02 (0.83 - 1.26)	0.83
HDL cholesterol	1.03 (0.80 - 1.31)	0.84
Triglycerides	1.09 (0.96 - 1.23)	0.18
BMI	0.90 (0.72 - 1.13)	0.36

BMI, body mass index; LDL, low-density lipoprotein; HDL, high-density lipoprotein. Two-sided P values for the adjusted Cox model are indicated. n=1,157.

**Table S5: Hazard ratios for 3-year MACE for the covariates used
in the adjusted Cox models in the US validation cohort**

	HR with 95% CI	P value
Age	1.60 (1.35 - 1.89)	<0.001
Gender	0.77 (0.57 - 1.05)	0.10
Blood pressure	1.01 (0.87 - 1.19)	0.86
Diabetes	0.83 (0.59 - 1.17)	0.29
Smoking	2.02 (1.39 - 2.92)	<0.001
LDL cholesterol	1.01 (0.86 - 1.17)	0.95
HDL cholesterol	0.81 (0.69 - 0.96)	0.02
Triglycerides	0.88 (0.73 - 1.06)	0.17
BMI	0.94 (0.81 - 1.11)	0.48

BMI, body mass index; LDL, low-density lipoprotein; HDL, high-density lipoprotein. Two-sided P values for the adjusted Cox model are indicated. n=2,149.

**Table S6: Hazard ratios for 3-year MACE for the covariates used
in the adjusted Cox models in the European validation cohort**

	HR with 95% CI	P value
Age	1.78 (1.40 - 2.28)	<0.001
Gender	1.06 (0.70 - 1.61)	0.77
Hypertension	1.25 (0.74 - 2.11)	0.40
Diabetes	1.53 (1.04 - 2.24)	0.03
Smoking	1.66 (1.00- 2.74)	0.05
LDL cholesterol	1.12 (0.89 - 1.42)	0.32
HDL cholesterol	0.94 (0.73 - 1.22)	0.66
Triglycerides	1.06 (0.87 - 1.29)	0.54

LDL, low-density lipoprotein; HDL, high-density lipoprotein. Two-sided P values for the adjusted Cox model are indicated. n=833.

Table S7: Gender-stratified Cox models for 3-year MACE in the discovery cohort

Female (n=421)	Quartile 1 (n=106)	Q2 (n=105)	Q3 (n=105)	Q4 (n=105)
Unadjusted HR	1	2.35 (0.83 - 6.65)	1.35 (0.43 - 4.25)	4.46 (1.68 - 11.86)**
Adjusted HR	1	2.46 (0.84 - 7.19)	1.46 (0.41 - 5.11)	5.00 (1.68 - 14.9)**
Male (n=736)	Q1 (n=185)	Q2 (n=184)	Q3 (n=183)	Q4 (n=184)
Unadjusted HR	1	1.19 (0.55 - 2.57)	0.64 (0.26 - 1.56)	3.25 (1.69 - 6.24)***
Adjusted HR	1	1.17 (0.53 - 2.58)	0.59 (0.24 - 1.46)	2.69 (1.34 - 5.41)**

The adjustment included age, sex, diabetes mellitus, blood pressure, low-density and high-density lipoprotein cholesterol levels, triglyceride levels, current smoking status and BMI.

Two-sided P values for the Cox model are indicated as follows ***P<0.001, **P<0.01. n=1,157.

Table S8: Gender-stratified Cox models for 3-year MACE in the US validation cohort

Female (n=773)	Q1 (n=194)	Q2 (n=194)	Q3 (n=195)	Q4 (n=190)
Unadjusted HR	1	1.11 (0.56 - 2.22)	1.41 (0.73 - 2.74)	2.30 (1.25 - 4.23)**
Adjusted HR	1	1.02 (0.52 - 2)	1.18 (0.61 - 2.31)	1.59 (0.79 - 3.2)
Male (n=1376)	Q1 (n=344)	Q2 (n=348)	Q3 (n=340)	Q4 (n=344)
Unadjusted HR	1	1.08 (0.59 - 1.99)	1.7 (0.98 - 2.94)	2.82 (1.70 - 4.70)***
Adjusted HR	1	1.02 (0.55 - 1.90)	1.38 (0.79 - 2.43)	1.96(1.13 - 3.39)*

The adjustment included age, sex, diabetes mellitus, blood pressure, low-density and high-density lipoprotein cholesterol levels, triglyceride levels, current smoking status and BMI.

Two-sided P values for the Cox model are indicated as follows ***P<0.001, **P<0.01, *P<0.05. n=2,149.

Table S9: Gender-stratified Cox models for 3-year MACE in the European validation cohort

Female (n=249)	Q1 (n=63)	Q2 (n=62)	Q3 (n=62)	Q4 (n=62)
Unadjusted HR	1	1.64 (0.64 - 4.2)	1.67 (0.65 - 4.30)	3.77 (1.61 - 8.80)**
Adjusted HR	1	1.82 (0.48 – 7.0)	1.66 (0.53 - 5.19)	2.27 (0.75 - 6.82)
Male (n=584)	Q1 (n=150)	Q2 (n=142)	Q3 (n=146)	Q4 (n=146)
Unadjusted HR	1	1.22 (0.65 - 2.32)	2.09(1.17 - 3.72)*	4.92 (2.89 - 8.35)***
Adjusted HR	1	0.98 (0.46 - 2.09)	0.93 (0.43 - 1.98)	2.37(1.16 - 4.84)*

The adjustment included age, sex, diabetes mellitus, hypertension, low-density and high-density lipoprotein cholesterol levels, triglyceride level and current smoking status. Two-sided P values for the Cox model are indicated as follows ***P<0.001, **P<0.01, *P<0.05. n=833.

Table S10: Hazard ratios for 3-year MACE for erythritol in different subgroups of the US validation cohort

Subgroup	n	Q4 vs. Q1 HR (95% CI)	P value	P for interaction
Age ≥ 70	608	2.06 (1.22 - 3.49)	0.007	0.61
Age < 70	1541	1.86 (1.12 - 3.08)	0.02	
Female	773	2.30 (1.25 - 4.23)	0.007	0.43
Male	1356	2.82 (1.70 - 4.70)	<0.001	
Hypertension	652	3.12 (1.25 - 7.76)	0.01	0.95
No Hypertension	1489	2.69 (1.71 - 4.24)	<0.001	
Diabetes	475	2.07 (0.93 - 4.57)	0.07	0.55
No Diabetes	1674	2.63 (1.69 - 4.09)	<0.001	
HbA1C≥5.7 %	1081	2.48 (1.45 - 4.24)	0.001	0.20
HbA1C<5.7 %	952	3.04 (1.62 - 5.68)	0.001	
GFR ≥ 60 ml/min/1.73m ³	1834	1.83 (1.18 - 2.85)	0.007	0.11
GFR <60 ml/min/1.73m ³	315	4.47 (1.82 - 11.0)	0.001	
BMI ≥27 kg/m ²	1346	2.69 (1.57 - 4.61)	<0.001	0.68
BMI <27 kg/m ²	803	2.81 (1.58 - 4.98)	<0.001	
CAD	1610	2.56 (1.67 - 3.94)	<0.001	0.58
No CAD	539	2.74 (0.98 - 7.64)	0.05	
Prior MI	797	2.17 (1.22 - 3.86)	0.008	0.12
No Prior MI	1223	3.26 (1.83 - 5.81)	<0.001	
LDL-c≥ 100 mg/dL	974	2.03 (1.18 - 3.52)	0.011	0.76
LDL-c<100 mg/dL	1175	3.23 (1.87 - 5.57)	<0.001	
HDL- c≥ 40 mg/dL	645	2.02 (1.04 - 3.92)	0.04	0.75
HDL-c<40 mg/dL	1504	2.96 (1.82 - 4.80)	<0.001	
Triglycerides ≥ 150	665	2.86 (1.38 - 5.92)	0.005	0.41
Triglycerides <150	1494	2.82 (1.76 - 4.53)	<0.001	

BMI, body mass index; CAD, coronary artery disease; GFR, glomerular filtration rate; HbA1C, hemoglobin A1C; HDL, high density lipoprotein; LDL, low density lipoprotein; MI, myocardial infarction. Two-sided P values are shown for the Cox model and for interaction with the groups. N numbers for each subset are indicated.

Table S11: Hazard ratios for 3-year MACE for erythritol in different subgroups of the European validation cohort

Subgroup	n	Q4 vs. Q1 HR (95% CI)	P value	P for interaction
Age ≥ 70	540	3.49 (2.12 - 5.73)	<0.001	0.86
Age < 70	293	3.08 (1.22 - 7.78)	0.02	
Female	249	3.77 (1.61 - 8.80)	0.002	0.28
Male	584	4.92 (2.89 - 8.35)	<0.001	
Hypertension	670	6.08 (1.31 - 28.1)	<0.001	0.61
No Hypertension	163	4.97 (3.05 - 8.09)	0.02	
Diabetes	232	5.16 (2.4 - 11.1)	<0.001	0.35
No Diabetes	601	2.96 (1.72 - 5.10)	<0.001	
HbA1C≥5.7 %	439	5.39 (2.96 - 9.81)	<0.001	0.05
HbA1C<5.7 %	394	2.13 (1.06 - 4.25)	0.03	
GFR ≥ 60 ml/min/1.73m ³	559	2.38 (1.32 - 4.31)	0.004	0.21
GFR <60 ml/min/1.73m ³	274	5.25 (2.82 - 9.76)	<0.001	
CAD	577	4.22 (2.58 - 6.89)	<0.001	0.86
No CAD	256	5.97 (1.75 - 20.4)	0.004	
Prior MI	413	4.69 (2.54 - 8.66)	<0.001	0.69
No Prior MI	419	3.48 (1.77 - 6.87)	<0.001	
LDL-c≥ 100 mg/dL	333	4.27 (1.94 - 9.37)	<0.001	0.98
LDL-c<100 mg/dL	479	3.92 (2.25 - 6.83)	<0.001	
HDL- c≥ 40 mg/dL	594	4.28 (2.4 - 7.62)	<0.001	0.99
HDL-c<40 mg/dL	216	4.15 (1.91 - 8.99)	<0.001	
Triglycerides ≥ 150	193	3.85 (1.50 - 9.87)	0.005	0.74
Triglycerides <150	388	3.71 (1.93 - 7.14)	<0.001	

CAD, coronary artery disease; GFR, glomerular filtration rate; HbA1C, hemoglobin A1C; HDL, high density lipoprotein; LDL, low density lipoprotein; MI, myocardial infarction. Two-sided P values are shown for the Cox model and for interaction with the groups. N numbers for each subset are indicated.

Table S12. Cox regression models in the discovery cohort

	HR with 95% CI	P value
Erythritol	1.31 (1.17 - 1.46)	<0.001
Age	1.20 (0.96 - 1.49)	0.12
Gender	1.10 (0.70 - 1.73)	0.68
Blood pressure	1.04 (0.87 - 1.24)	0.67
Diabetes	1.16 (0.73 - 1.84)	0.54
Smoking	1.41 (0.82 - 2.42)	0.22
LDL cholesterol	1.04 (0.84 - 1.28)	0.72
HDL cholesterol	1.04 (0.81 - 1.32)	0.77
Triglycerides	1.11 (0.99 - 1.25)	0.09
BMI	0.97 (0.78 - 1.21)	0.79

Hazard ratio for 3-year MACE per arbitrary unit of Erythritol (untargeted metabolomics) with covariates used for adjustment. BMI, body mass index; HDL, high density lipoprotein; LDL, low density lipoprotein. Two-sided P values are shown for the adjusted Cox model. n=1,157.

Table S13. Cox regression analysis in US validation cohort

	HR with 95% CI	P value
Erythritol	1.21 (1.12 - 1.31)	<0.001
Age	1.69 (1.44 - 1.98)	<0.001
Gender	0.76 (0.56 - 1.03)	0.08
Blood pressure	1.00 (0.86 - 1.17)	0.98
Diabetes	0.82 (0.58 - 1.16)	0.26
Smoking	1.97 (1.35 - 2.88)	<0.001
LDL cholesterol	1.03 (0.88 - 1.19)	0.74
HDL cholesterol	0.80 (0.68 - 0.95)	0.01
Triglycerides	0.89 (0.74 - 1.07)	0.22
BMI	0.96 (0.82 - 1.12)	0.60

Hazard ratio for 3-year MACE per μM of erythritol with covariates used for adjustment. BMI, body mass index; HDL, high density lipoprotein; LDL, low density lipoprotein. Two-sided P values are shown for the adjusted Cox model. n=2,149.

Table S14. Cox regression analysis in the European validation cohort

	HR with 95% CI	P value
Erythritol	1.16 (1.05 - 1.30)	0.005
Age	2.01 (1.6 - 2.54)	<0.001
Gender	1.07 (0.7 - 1.63)	0.76
Hypertension	1.25 (0.73 - 2.13)	0.41
Diabetes	1.68 (1.14 - 2.47)	0.009
Smoking	1.65 (1.01 - 2.71)	0.05
LDL cholesterol	1.09 (0.82 - 1.43)	0.57
HDL cholesterol	0.96 (0.74 - 1.24)	0.75
Triglycerides	1.14 (0.95 - 1.36)	0.16

Hazard ratio for 3-year MACE per μM of erythritol with covariates used for adjustment. HDL, high density lipoprotein; LDL, low density lipoprotein. Two-sided P values are shown for the adjusted Cox model. n=833.